RBC Capital Maintains Outperform on Illumina, Raises Price Target to $310
10/5/2026
Impact: 80
Healthcare
RBC Capital analyst Dan Leonard has maintained an Outperform rating on Illumina (NASDAQ: ILMN) and raised the price target from $230 to $310. This adjustment reflects a positive outlook for the company's performance in the market.
AI summary, not financial advice
Share: